Freeman Kevin's most recent trade in Health Catalyst Inc was a trade of 4,747 Common Stock done at an average price of $3.6 . Disclosure was reported to the exchange on June 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.63 per share. | 02 Jun 2025 | 4,747 | 379,665 (1%) | 0% | 3.6 | 17,254 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.58 per share. | 03 Mar 2025 | 10,800 | 384,412 (1%) | 0% | 4.6 | 49,433 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 140,000 | 376,950 (1%) | 0% | 0 | Common Stock | |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 18,262 | 395,212 (1%) | 0% | 0 | Common Stock | |
| Old Dominion Freight Line | Kevin Freeman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 5,268 | 59,333 (0%) | 0% | 0 | Common Stock | |
| Old Dominion Freight Line | Kevin Freeman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 197.20 per share. | 07 Feb 2025 | 933 | 54,532 (0%) | 0% | 197.2 | 183,988 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 197.20 per share. | 07 Feb 2025 | 709 | 55,991 (0%) | 0% | 197.2 | 139,815 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 197.20 per share. | 07 Feb 2025 | 526 | 55,465 (0%) | 0% | 197.2 | 103,727 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 197.20 per share. | 07 Feb 2025 | 467 | 54,065 (0%) | 0% | 197.2 | 92,092 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | D. Freeman Kevin | Director | Purchase of securities on an exchange or from another person at price $ 0.81 per share. | 24 Dec 2024 | 10,000 | 44,769 (0%) | 0% | 0.8 | 8,134 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.97 per share. | 01 Dec 2024 | 11,431 | 244,450 (0%) | 0% | 9.0 | 102,573 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 8.94 per share. | 01 Dec 2024 | 7,500 | 236,950 (0%) | 0% | 8.9 | 67,073 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.64 per share. | 17 Oct 2024 | 1,300 | 34,769 (0%) | 0% | 2.6 | 3,432 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.70 per share. | 16 Oct 2024 | 5,000 | 80,000 (0%) | 0% | 2.7 | 13,500 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.70 per share. | 16 Oct 2024 | 5,000 | 33,469 (0%) | 0% | 2.7 | 13,500 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 7.22 per share. | 03 Sep 2024 | 7,500 | 255,881 (0%) | 0% | 7.2 | 54,174 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.27 per share. | 03 Sep 2024 | 2,772 | 263,381 (0%) | 0% | 7.3 | 20,150 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.38 per share. | 20 Jun 2024 | 2,500 | 28,469 (0%) | 0% | 2.4 | 5,950 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 6.53 per share. | 11 Jun 2024 | 7,500 | 266,153 (0%) | 0% | 6.5 | 49,008 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 03 Jun 2024 | 2,951 | 273,653 (0%) | 0% | 6.5 | 19,280 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.98 per share. | 22 Apr 2024 | 2,500 | 25,969 (0%) | 0% | 3.0 | 7,450 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | 09 Apr 2024 | 2,063 | 18,063 (0%) | 0% | 0 | Common Stock | ||
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.05 per share. | 01 Mar 2024 | 4,540 | 276,604 (0%) | 0% | 8.1 | 36,552 | Common Stock |
| Health Catalyst Inc | Freeman Kevin Lee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 110,000 | 277,810 (0%) | 0% | 0 | Common Stock | |
| Health Catalyst Inc | Lee Kevin Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 3,334 | 281,144 (0%) | 0% | 0 | Common Stock | |
| Old Dominion Freight Line | Kevin Freeman | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 435.33 per share. | 08 Feb 2024 | 845 | 28,772 (0%) | 0% | 435.3 | 367,854 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 435.33 per share. | 08 Feb 2024 | 529 | 29,881 (0%) | 0% | 435.3 | 230,290 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 435.33 per share. | 08 Feb 2024 | 422 | 28,350 (0%) | 0% | 435.3 | 183,709 | Common Stock |
| Old Dominion Freight Line | Freeman Kevin | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 435.33 per share. | 08 Feb 2024 | 264 | 29,617 (0%) | 0% | 435.3 | 114,927 | Common Stock |
| Old Dominion Freight Line | Freeman Kevin | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 435.16 per share. | 08 Feb 2024 | 197 | 30,410 (0%) | 0% | 435.2 | 85,727 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 2,750 | 30,607 (0%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Health Catalyst Inc | Lee Kevin Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.45 per share. | 01 Dec 2023 | 2,921 | 167,810 (0%) | 0% | 7.5 | 21,762 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.24 per share. | 01 Jun 2023 | 1,038 | 179,191 (0%) | 0% | 11.2 | 11,666 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 1,819 | 179,665 (0%) | 0% | 0 | Common Stock | |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.29 per share. | 01 Mar 2023 | 1,569 | 177,846 (0%) | 0% | 14.3 | 22,419 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 1,264 | 180,929 (0%) | 0% | 0 | Common Stock | |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 349.00 per share. | 11 Feb 2023 | 856 | 29,076 (0%) | 0% | 349 | 298,744 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 355.96 per share. | 11 Feb 2023 | 642 | 27,857 (0%) | 0% | 356.0 | 228,526 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 355.96 per share. | 11 Feb 2023 | 577 | 28,499 (0%) | 0% | 356.0 | 205,389 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 349.00 per share. | 11 Feb 2023 | 428 | 29,932 (0%) | 0% | 349 | 149,372 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 2,040 | 30,911 (0%) | 0% | 0 | Common Stock | |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 355.00 per share. | 08 Feb 2023 | 367 | 30,360 (0%) | 0% | 355 | 130,285 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 355.00 per share. | 08 Feb 2023 | 184 | 30,727 (0%) | 0% | 355 | 65,320 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 3,615 | 28,871 (0%) | 0% | 0 | Common Stock | |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Growth Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.65 per share. | 01 Dec 2022 | 2,446 | 179,415 (0%) | 0% | 10.6 | 26,049 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.41 per share. | 28 Oct 2022 | 10,000 | 75,000 (0%) | 0% | 1.4 | 14,100 | Common Stock |
| Health Catalyst Inc | Kevin Lee Freeman | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2022 | 120,000 | 181,861 (0%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 19 May 2022 | 5,000 | 65,000 (0%) | 0% | 1.3 | 6,650 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.71 per share. | 18 Apr 2022 | 5,000 | 60,000 (0%) | 0% | 1.7 | 8,550 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 293.95 per share. | 11 Feb 2022 | 943 | 25,256 (0%) | 0% | 294.0 | 277,195 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 295.65 per share. | 11 Feb 2022 | 750 | 27,267 (0%) | 0% | 295.7 | 221,738 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 295.65 per share. | 11 Feb 2022 | 562 | 26,199 (0%) | 0% | 295.6 | 166,155 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 295.65 per share. | 11 Feb 2022 | 506 | 26,761 (0%) | 0% | 295.7 | 149,599 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 295.65 per share. | 11 Feb 2022 | 375 | 28,017 (0%) | 0% | 295.7 | 110,869 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 5,776 | 26,585 (0%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.96 per share. | 19 Jan 2022 | 5,000 | 55,000 (0%) | 0% | 2.0 | 9,806 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 15 Dec 2021 | 5,000 | 50,000 (0%) | 0% | 2.3 | 11,400 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.34 per share. | 06 Dec 2021 | 5,000 | 45,000 (0%) | 0% | 2.3 | 11,700 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.17 per share. | 29 Oct 2021 | 2,000 | 40,000 (0%) | 0% | 3.2 | 6,340 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.19 per share. | 21 Oct 2021 | 2,000 | 38,000 (0%) | 0% | 3.2 | 6,380 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.37 per share. | 19 Oct 2021 | 3,000 | 36,000 (0%) | 0% | 3.4 | 10,107 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.88 per share. | 23 Sep 2021 | 3,000 | 33,000 (0%) | 0% | 3.9 | 11,631 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.04 per share. | 05 Apr 2021 | 5,000 | 30,000 (0%) | 0% | 2.0 | 10,200 | Common Stock |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 2,888 | 22,949 (0%) | 0% | 0 | Common Stock | |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 212.21 per share. | 11 Feb 2021 | 808 | 21,091 (0%) | 0% | 212.2 | 171,466 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 212.21 per share. | 11 Feb 2021 | 553 | 22,396 (0%) | 0% | 212.2 | 117,352 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 212.21 per share. | 11 Feb 2021 | 497 | 21,899 (0%) | 0% | 212.2 | 105,468 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 212.21 per share. | 11 Feb 2021 | 282 | 20,809 (0%) | 0% | 212.2 | 59,843 | Common Stock |
| Old Dominion Freight Line | Kevin Freeman | EVP & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 4,327 | 20,061 (0%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.57 per share. | 04 Sep 2020 | 5,000 | 25,000 (0%) | 0% | 2.6 | 12,848 | Common Stock |